Tech Company Financing Transactions
Agomab Funding Round
Agomab, based in Ghent, raised $89 million in funding from Invus and Sanofi Ventures.
Transaction Overview
Company Name
Announced On
10/25/2024
Transaction Type
Venture Equity
Amount
$89,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to further advance the ongoing clinical development of its lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor of ALK5 (TGFß1R), in patients with fibrostenosing Crohn's disease (FSCD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Franklin Rooseveltlaan 348
Ghent, 9000
Belgium
Ghent, 9000
Belgium
Phone
Undisclosed
Website
Email Address
Overview
Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tim Knotnerus
Chief Financial Officer
Tolga Hassan
Chief Medical Officer
Philippe Wiesel
Chief Scientific Officer
Paolo Michieli
VP - Bus. Development
Torsten Dreier
VP - Bus. Development
Paul van der Horst
VP - General Counsel
Ellen Lefever
VP - R & D
Ramon Bosser
VP - R & D
Reginald Brys
Browse more venture capital transactions:
Prev: 10/25/2024: Vyntelligence venture capital transaction
Next: 10/25/2024: Yoga Joint venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs